GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced a worldwide licensing agreement with Eli ...

GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered a collaboration agreement ...

Confo Therapeutics’ business development team is on a roll. Weeks after licensing its lead candidate to Eli Lilly, the Belgian biotech has landed a 168 million euro ($182 million) deal with Daiichi ...

The pain drug market has many products, but there’s still a need for pills with better properties, such as avoiding addiction. Eli Lilly sees potential in the non-opioid pain drug research from Confo ...

Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH ...

Roche has entered into a neurological and developmental disorder drug discovery pact with Confo Therapeutics. The agreement gives Roche a potential source of small molecule agonists of an undisclosed ...

Ghent, Belgium – October 8, 2025 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has secured a EUR 1 million ...

Eli Lilly reached a deal with Confo Therapeutics to gain licensing to Confo’s non-opioid neuropathic pain candidate, CFTX-1554, the companies announced Thursday. In the deal, Confo will receive $630 ...

Candidate selection underscores Confo’s ability to rapidly advance differentiated GPCR-targeting therapeutics and its focus on metabolic and endocrine disorders Cedric Ververken, CEO of Confo ...

Proceeds to support Phase 1 clinical trials for two proprietary programs, and to advance two additional programs to IND approval Company to expand R&D efforts to discover additional development ...

Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if Lilly proceeds with a second product candidate Tiered royalties payable ...